ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 258 entries already.
Real Quality. Real Results. With cell & gene therapies, the process is the product – so ensuring high-quality starting material is a critical first step in maximizing your results.
The bioeconomy can be a major driver in bringing circularity, sustainability and competitive production to Europe as it aims towards becoming climate-neutral and more self-sufficient.
Jeff Borcherding, President of Immunovia’s US subsidiary since April 2022, has been the new Global CEO of Sweden’s Immunovia AB since the end of April.
The French Abivax SA has had a new CEO since the beginning of May. Marc de Garidel took over the position and became interim chairman of the supervisory board.
The biopharmaceutical company ImmunOs Therapeutics AG has appointed Michael A. Curran, PhD, as Chairman of the Company´s Scientific Advisory Board.
Biotech innovator Biosyntia ApS, the latest addition to the ECBF, is applying proprietary biological processes to produce sustainable nutritional ingredients – a mission that has captured the imagination of seasoned biotech investors and major ingredient players.
Steve Jones took over the role of Chief Financial Officer (CFO) at the biotech company Ingenza Ltd (UK) at the beginning of April. He brings many years of experience and expertise in finance, having held a variety of senior positions.
Sweden’s Belach Bioteknik has been partnering mostly with researchers and pharma customers to design suited bioreactor systems for biomanufacturing. Most recently, the company has entered the growing cultured meat sector, in which many companies are currently scaling up their production and thus need expertise to get optimal results.
Swedish Neogap Therapeutics got a new Chief Medical Officer (CMO). Dr Hanjing Xie has recently started her new position at the Stockholm-based biotech company.
From its all-time high in August 2021 the largest and most important index for the biotech industry also in Europe (NBI) lost around 25%. After a period of excessive capital inflows, money is much harder to come by these days. The answer can only be more creativity in structuring deals.